16 October 2025
Respiratory syncytial virus immunisation
Following an update to UKHSA guidance on respiratory syncytial virus (RSV), the Respiratory syncytial virus immunisation treatment summary in BNF for Children (BNFC) has been revised to include new guidance on immunisation of very and extremely preterm infants (those born before 32 weeks gestation); the long-acting monoclonal antibody nirsevimab should be used for immunisation in these infants. In addition, the existing guidance on immunisation of high-risk infants and young children has been updated to include the timing of administration of nirsevimab, which is recommended as first-line; palivizumab can be used if nirsevimab is not available. A new monograph has also been created in BNFC for nirsevimab.
